RxSight, Inc. (NASDAQ:RXST) Shares Sold by Sara Bay Financial

Sara Bay Financial trimmed its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 8.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 99,864 shares of the company's stock after selling 8,989 shares during the quarter. RxSight accounts for approximately 1.3% of Sara Bay Financial's investment portfolio, making the stock its 12th largest position. Sara Bay Financial owned 0.25% of RxSight worth $3,376,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in RXST. Renaissance Technologies LLC raised its stake in shares of RxSight by 46.6% during the second quarter. Renaissance Technologies LLC now owns 230,100 shares of the company's stock valued at $13,845,000 after acquiring an additional 73,100 shares in the last quarter. Amalgamated Bank raised its holdings in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares in the last quarter. Hsbc Holdings PLC bought a new position in RxSight in the second quarter worth approximately $242,000. Public Employees Retirement Association of Colorado bought a new stake in RxSight during the 2nd quarter valued at $168,000. Finally, Canada Pension Plan Investment Board bought a new position in RxSight in the second quarter worth about $156,000. Hedge funds and other institutional investors own 78.78% of the company's stock.

RxSight Stock Down 2.5 %

Shares of NASDAQ:RXST traded down $0.79 during midday trading on Friday, reaching $30.39. The company's stock had a trading volume of 627,464 shares, compared to its average volume of 596,025. The stock has a fifty day moving average of $38.97 and a 200 day moving average of $46.70. RxSight, Inc. has a twelve month low of $26.29 and a twelve month high of $66.54.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RXST. Stifel Nicolaus cut their price target on shares of RxSight from $40.00 to $35.00 and set a "hold" rating on the stock in a report on Monday, January 13th. Wells Fargo & Company decreased their price target on RxSight from $42.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Needham & Company LLC restated a "buy" rating and set a $66.00 price objective on shares of RxSight in a report on Monday, January 13th. UBS Group assumed coverage on shares of RxSight in a research note on Friday, December 6th. They issued a "buy" rating and a $52.00 target price for the company. Finally, Jefferies Financial Group started coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a "buy" rating and a $72.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $58.13.

Insiders Place Their Bets

In other news, insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $50.64, for a total value of $156,984.00. Following the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,139,337.44. This trade represents a 6.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the transaction, the director now owns 10,902 shares of the company's stock, valued at $500,183.76. The trade was a 25.76 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,797 shares of company stock valued at $1,649,949. Company insiders own 9.36% of the company's stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.